News & Media
Learn more about the latest happenings at Otsuka. Select to see US news or read our press releases. You can also stay up to date with our global news in the link below.
![Image](/sites/g/files/qhldwo9046/files/styles/max_325x325/public/2020-11/image-full-bleed-copy%403x.jpg?itok=wwRC_Cyh)
Media Contact:
Senior Director, External Communications,
Otsuka America Pharmaceutical, Inc
Maximizes Efficiency of Global Development and Commercialization Committed Capital and Potential Milestone Payments from Otsuka of up to $865 Million, including $208 million or more in Upfront Payment and Development Funding, as well as Tiered, Double-Digit Royalties Total Committed Development Funding from all of Akebia’s Vadadustat Collaborations Plus Cash Exceeds $600 Million Akebia
PRINCETON, N.J., APRIL 19, 2017 - When a cowboy with a message of compassion and a desire to eliminate stigma connects with a company whose mission is creating products for better mental health worldwide, good things will happen. Jason DeShaw, a singer/songwriter and national award-winning mental health advocate from Montana, recently visited the Otsuka offices in Princeton, New Jersey to share
Acquisition of clinical-stage company in ADHD widens Otsuka’s presence in mental health Tokyo, Japan – March 3, 2017 – Otsuka Pharmaceutical Co., Ltd. (OPC) today announces an agreement with Neurovance, Inc. (Neurovance) under which OPC has agreed to acquire Neurovance, a privately held, venture-funded, clinical stage pharmaceutical company focused on attention-deficit hyperactivity
Funds Vadadustat Global Phase 3 PRO2TECT and INNO2VATE Studies Committed Capital and Milestone Payments Potentially Exceed $1 Billion Akebia and Otsuka Share Revenue and Commercialization Costs Equally Akebia to Host Conference Call at 8:30 a.m. Eastern Time Today CAMBRIDGE, MA & TOKYO, JAPAN -- December 20, 2016 Akebia Therapeutics, Inc. (NASDAQ: AKBA) and